Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review

Timothy J. Craig, Lynda C. Schneider, Andrew J. Macginnitie

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Presently, medications approved for children with Hereditary Angioedema (HAE) are extremely limited. This is especially the case for children under 12 years of age. For this reason we reviewed and summarized the data on treatment of children with HAE. Available data indicate that plasma derived C1-inhibitor is a safe, effective treatment option for HAE in pediatric patients, including those below 12 years of age. Other therapies are also appear safe for the under 12 year of age, but less data are available. Importantly, home-based treatment of HAE in this age group appears to be safe and effective and can improve quality of life. These findings support current HAE consensus guidelines which strongly recommend the use of plasma derived C1-inhibitor as a first-line treatment in children and encourage home and self-treatment.

Original languageEnglish (US)
Pages (from-to)537-544
Number of pages8
JournalPediatric Allergy and Immunology
Volume26
Issue number6
DOIs
StatePublished - Sep 1 2015

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review'. Together they form a unique fingerprint.

  • Cite this